| Name | Title | Contact Details |
|---|
WithMe Health replaces an employer`s pharmacy benefit manager (PBM) with a personalized medication guidance solution that greatly improves on and expands the scope of services available in the market today. Our modern technology and rich datasets allow consistent application of proven science to create individualized medication experiences for employees and their families that are proactive, adaptive, convenient and engaging. With an innovative, outcomes-oriented business model that aligns interests across the pharmaceutical value chain, WithMe Health optimizes health outcomes and value while substantially reducing costs for employers.
Race Across AMerica is a Mesa, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Patient First is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
People come to Murad when they`re ready to transform the life of their skin. Murad guarantees that transformation because only Murad combines advanced scientific research and practical clinical experience to create high performance skincare products, dietary supplements and lifestyle programs that help people look and feel their absolute best. As America`s first authentic doctor-developed brand, Murad remains true to the scientific principles of its founder, world-renowned dermatologist Howard Murad, M.D. Shaped by his Inclusive Health philosophy and inspired by the real problems of the more than 50,000 patients and clients who have visited his Los Angeles dermatology practice and Inclusive Health Spa®, his award-winning formulas have helped millions to resolve their skin issues. Through more than fifty years of research, Dr. Murad has established that beauty and health are vitally linked and best achieved through an Inclusive approach that improves every cell in the body. The result? The Murad Glow!
Third Pole, Inc. is a US-based company developing next generation life-saving cardiopulmonary therapies. We are building on our team`s legacy in inhaled nitric oxide (NO), the current standard of care, to develop next generation life-saving heart and lung therapies.